Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial

A VIVA Substudy

Ina Qvist*, Rikke Søgaard, Jes S Lindholt, Vibeke Lorentzen, Jesper Hallas, Lars Frost

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Objective: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. Methods: This was a population based cohort study. The study population consisted of 65–74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80% over five years of follow up was used as a categorical cut off for adherence. Results: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65% and 62% initiated antiplatelet and statin treatment, 57% and 59% persisted with antiplatelet and statin use, and 60% and 57% were adherent, respectively. Among users at baseline, 73% and 69% had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79% and 73% persisted with their antiplatelet and statin treatment, and 89% and 83% were adherent, respectively. Conclusion: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57–60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.

Original languageEnglish
JournalEuropean Journal of Vascular and Endovascular Surgery
Volume57
Issue number3
Pages (from-to)442-450
ISSN1078-5884
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Abdominal Aortic Aneurysm
Pharmaceutical Preparations
Prescriptions
Population
Cohort Studies

Keywords

  • Cardiovascular diseases
  • Medication adherence
  • Medication persistence
  • Registers
  • Screening
  • Secondary prevention

Cite this

@article{444745fff1f14d4ebf9b30f5cce91ba2,
title = "Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy",
abstract = "Objective: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. Methods: This was a population based cohort study. The study population consisted of 65–74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80{\%} over five years of follow up was used as a categorical cut off for adherence. Results: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65{\%} and 62{\%} initiated antiplatelet and statin treatment, 57{\%} and 59{\%} persisted with antiplatelet and statin use, and 60{\%} and 57{\%} were adherent, respectively. Among users at baseline, 73{\%} and 69{\%} had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79{\%} and 73{\%} persisted with their antiplatelet and statin treatment, and 89{\%} and 83{\%} were adherent, respectively. Conclusion: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57–60{\%}. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80{\%}. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.",
keywords = "Cardiovascular diseases, Medication adherence, Medication persistence, Registers, Screening, Secondary prevention",
author = "Ina Qvist and Rikke S{\o}gaard and Lindholt, {Jes S} and Vibeke Lorentzen and Jesper Hallas and Lars Frost",
note = "Copyright {\circledC} 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.",
year = "2019",
month = "3",
doi = "10.1016/j.ejvs.2018.09.023",
language = "English",
volume = "57",
pages = "442--450",
journal = "European Journal of Vascular and Endovascular Surgery",
issn = "1078-5884",
publisher = "Elsevier",
number = "3",

}

Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial : A VIVA Substudy. / Qvist, Ina; Søgaard, Rikke; Lindholt, Jes S; Lorentzen, Vibeke; Hallas, Jesper; Frost, Lars.

In: European Journal of Vascular and Endovascular Surgery, Vol. 57, No. 3, 03.2019, p. 442-450.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial

T2 - A VIVA Substudy

AU - Qvist, Ina

AU - Søgaard, Rikke

AU - Lindholt, Jes S

AU - Lorentzen, Vibeke

AU - Hallas, Jesper

AU - Frost, Lars

N1 - Copyright © 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

PY - 2019/3

Y1 - 2019/3

N2 - Objective: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. Methods: This was a population based cohort study. The study population consisted of 65–74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80% over five years of follow up was used as a categorical cut off for adherence. Results: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65% and 62% initiated antiplatelet and statin treatment, 57% and 59% persisted with antiplatelet and statin use, and 60% and 57% were adherent, respectively. Among users at baseline, 73% and 69% had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79% and 73% persisted with their antiplatelet and statin treatment, and 89% and 83% were adherent, respectively. Conclusion: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57–60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.

AB - Objective: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. Methods: This was a population based cohort study. The study population consisted of 65–74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80% over five years of follow up was used as a categorical cut off for adherence. Results: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65% and 62% initiated antiplatelet and statin treatment, 57% and 59% persisted with antiplatelet and statin use, and 60% and 57% were adherent, respectively. Among users at baseline, 73% and 69% had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79% and 73% persisted with their antiplatelet and statin treatment, and 89% and 83% were adherent, respectively. Conclusion: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57–60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.

KW - Cardiovascular diseases

KW - Medication adherence

KW - Medication persistence

KW - Registers

KW - Screening

KW - Secondary prevention

U2 - 10.1016/j.ejvs.2018.09.023

DO - 10.1016/j.ejvs.2018.09.023

M3 - Journal article

VL - 57

SP - 442

EP - 450

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

SN - 1078-5884

IS - 3

ER -